October 19, 2022, 9:00-9:30 AM ET / 3:00-3:30 PM CET
Overview
In the management of non-small cell lung cancer, targeted therapies directed against proteins involved in oncogenesis and disease progression have revolutionized treatment, improving outcomes for select patients. Recent research efforts have been focused on the discovery and exploitation of novel therapeutic targets, with the goal of expanding the reach of effective targeted therapy.
In this live webcast, the faculty expert will provide recent updates on the use of targeted therapy directed toward emerging cell surface targets of interest in the management of metastatic NSCLC. These presentations will focus on key ongoing trials, as well as important data explaining how these agents may impact on the treatment landscape of NSCLC in the future.
Target Audience
This educational activity is directed toward a global audience of community and academic medical oncologists, pathologists, molecular pathologists, thoracic surgeons, NPs/PAs, pharmacists, and nurses.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Determine key evidence from trials that have evaluated the efficacy and safety of HER2-, HER3-, and TROP2-targeted approaches to manage patients with advanced NSCLC
- Explain how recent findings from investigations on therapies targeting HER2, HER3, and TROP2 pathways should be considered in the context of evolving treatment paradigms in advanced NSCLC.
Edward Garon
Professor of Medicine (Hematology/Oncology)
David Geffen School of Medicine at the University of California, Los Angeles
Los Angeles, CA
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.